COVID19: Pfizer-BioNTech Seek Emergency Approval For Their Vaccine in US
Mumbai: American giant Pfizer Inc., along with its German partner BioNTech, has sought emergency approval for its COVID-19 vaccine, which has shown 95 percent efficacy in preventing the deadly virus. In particular, this is the first major step that will help eradicate the virus that holds the world hostage.
The application was made in a video posted on the suspect’s website, Reuters quoted Pfizer chief executive Albert Borla as saying. The application also gives safety data on its test participants, children (12–15 years), as well as adults (ages 56–85).
If the reports are to be believed, the FDA is expected to grant approval by mid-December. After which the company will start shipping its vaccine supplements. They are hoping to produce a dose of 50 million vaccines this year, which could help immunize 25 million people.
Also Read: Our COVID19 Vaccine 95% Effective, Had No Serious Safety Concerns: Pfizer
The news comes after the Pfizer COVID-19 vaccine showed 95 percent efficacy in its late-stage trials. They also said that they could start delivery of vaccination before December this year if all went well.
The joint statement to the two companies states that 41,135 adults have not had any serious side effects. The most common reactions were that 3.7 percent of the participants experienced fatigue and 2 percent experienced a headache.
(With Agency Inputs)
Follow us on Twitter, Instagram, and like us on Facebook for the latest updates and interesting stories.
